van Litsenburg Raphaële R L, Kunst Annemieke, Huisman Jaap, Ket Johannes C F, Kaspers Gertjan J L, Gemke Reinoud J B J
Department of Pediatrics, Division of Oncology-Hematology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands (RRLVL, GJLK).
Department of Pediatrics, VU University Medical Center Amsterdam, Amsterdam, the Netherlands (AK, RJBJG)
Med Decis Making. 2014 Jan;34(1):21-32. doi: 10.1177/0272989X13497263. Epub 2013 Jul 25.
Measuring utilities and health-related quality of life (HRQL) in children is challenging due to their cognitive abilities and changing developmental stages.
. To identify methodological issues on utility measurements in children, we performed a systematic review on utilities measured with a single instrument, the Health Utilities Index (HUI), in pediatric acute lymphoblastic leukemia (ALL). The secondary goal was to facilitate future cost-utility analyses without the need for time-consuming assessments. Data Sources. PubMed, Embase, Cochrane Library, CINAHL, and PsycINFO were searched from inception to June 2012. Studies had to report on utility scores in pediatric ALL, either on or after treatment, to be included.
. Fifteen studies were included. Most studies had methodological shortcomings, which mainly concerned
and definition and representativeness of the study group. Utility scores were dependent on treatment variables, and there generally was an improvement in HRQL as treatment or survivorship advanced. In general, proxy-respondents were less reliable for subjective phenomena than for observable conditions. HUI2 and HUI3 scores were not interchangeable. Limitations. Studies may have been missed because no validated search method for utility studies exists, due to language bias or the exclusion of non-peer-reviewed papers.
. Most studies in this review were methodologically suboptimal. Future developments should focus on including developmentally appropriate items for the whole pediatric age group. Adding disease-specific domains may enhance the sensitivity and responsiveness of instruments. Efforts should be undertaken to elicit valuation of health states from older children and teenagers as much as possible. For now, it remains difficult to make valid and informed decisions on the financing of interventions until health state valuation in children has become more methodologically robust.
由于儿童的认知能力和不断变化的发育阶段,测量儿童的效用值和健康相关生活质量(HRQL)具有挑战性。
为了确定儿童效用值测量中的方法学问题,我们对使用单一工具健康效用指数(HUI)测量小儿急性淋巴细胞白血病(ALL)的效用值进行了系统评价。次要目标是便于未来进行成本效用分析,而无需耗时的评估。数据来源。检索了从创刊至2012年6月的PubMed、Embase、Cochrane图书馆、CINAHL和PsycINFO。纳入的研究必须报告小儿ALL治疗期间或治疗后的效用值分数。
纳入了15项研究。大多数研究存在方法学缺陷,主要涉及研究设计以及研究组的定义和代表性。效用值分数取决于治疗变量,并且随着治疗或生存期的推进,HRQL通常会有所改善。一般来说,代理人受访者对于主观现象不如对于可观察状况可靠。HUI2和HUI3分数不可互换。局限性。由于不存在经过验证的效用研究检索方法、语言偏倚或排除非同行评审论文,可能遗漏了一些研究。
本综述中的大多数研究在方法学上并不理想。未来的发展应侧重于为整个儿童年龄组纳入适合其发育阶段的项目。增加特定疾病领域可能会提高工具的敏感性和反应性。应努力尽可能多地获取大龄儿童和青少年对健康状态的估值。目前,在儿童健康状态估值在方法学上变得更加稳健之前,很难就干预措施的资金投入做出有效且明智的决策。